Genentech Avastin Labeling Will Reflect New Data On Thromboembolic Events
Executive Summary
Genentech is in discussions with FDA on revisingAvastin labeling to reflect an increased risk of thromboembolic events
You may also be interested in...
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month
Genentech is launching its oncologic Avastin at a wholesale acquisition cost of $2,200 per dose for the average colorectal cancer patient